KR101055305B1 - Method for producing a virus containing two or more target genes simultaneously - Google Patents

Method for producing a virus containing two or more target genes simultaneously Download PDF

Info

Publication number
KR101055305B1
KR101055305B1 KR1020080072102A KR20080072102A KR101055305B1 KR 101055305 B1 KR101055305 B1 KR 101055305B1 KR 1020080072102 A KR1020080072102 A KR 1020080072102A KR 20080072102 A KR20080072102 A KR 20080072102A KR 101055305 B1 KR101055305 B1 KR 101055305B1
Authority
KR
South Korea
Prior art keywords
virus
amplicon
target genes
herpes simplex
plasmid
Prior art date
Application number
KR1020080072102A
Other languages
Korean (ko)
Other versions
KR20100011054A (en
Inventor
황동연
Original Assignee
차의과학대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 차의과학대학교 산학협력단 filed Critical 차의과학대학교 산학협력단
Priority to KR1020080072102A priority Critical patent/KR101055305B1/en
Publication of KR20100011054A publication Critical patent/KR20100011054A/en
Application granted granted Critical
Publication of KR101055305B1 publication Critical patent/KR101055305B1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 2 종 이상의 표적 유전자를 각각 별도의 헤르페스 심플렉스 바이러스 앰플리콘 플라스미드(Herpes simplex virus amplicon plasmid)에 재조합시켜 얻어진 2 종 이상의 재조합 플라스미드를, fHSV△pac△27 0+ 및 pEBHICP27과 함께 수용 세포에 공동-형질도입시켜 패키징(packaging)시키는 단계를 포함하는, 2 종 이상의 표적 유전자를 동시에 함유하는 바이러스의 제조방법을 제공한다.The present invention provides two or more recombinant plasmids obtained by recombining two or more target genes into separate herpes simplex virus amplicon plasmids, together with fHSVΔpacΔ27 0+ and pEBHICP27. It provides a method for producing a virus containing two or more target genes at the same time, comprising the step of co-transduction and packaging.

헤르페스 심플렉스 바이러스 앰플리콘 플라스미드 Herpes Simplex Virus Amplicon Plasmid

Description

2 종 이상의 표적 유전자를 동시에 함유하는 바이러스의 제조방법{Method for producing viruses co-packaged with two or more target genes}Method for producing viruses co-packaged with two or more target genes}

본 발명은 2 종 이상의 표적 유전자를 동시에 함유하는 바이러스의 제조방법에 관한 것으로, 더욱 상세하게는 2 종 이상의 표적 유전자를 각각 별도의 헤르페스 심플렉스 바이러스 앰플리콘 플라스미드(Herpes simplex virus amplicon plasmid)에 재조합시켜 얻어진 2 종 이상의 재조합 플라스미드를 수용 세포에 공동-형질도입시켜 패키징시키는 단계를 포함하는 2 종 이상의 표적 유전자를 동시에 함유하는 바이러스의 제조방법에 관한 것이다.The present invention relates to a method for producing a virus containing two or more target genes simultaneously, and more particularly, by recombining two or more target genes into a separate herpes simplex virus amplicon plasmid. The present invention relates to a method for producing a virus containing two or more target genes simultaneously, the method comprising co-transduction and packaging of two or more recombinant plasmids obtained into recipient cells.

헤르페스 심플렉스 바이러스 앰플리콘 플라스미드(Herpes simplex virus amplicon plasmid, HSV amplicon plasmid)는 DNA 복제 origin (oriS) 과 virion DNA cleavage/packaging (pac) 에 필요한 최소한의 바이러스 DNA 요소(viral DNA element)와 박테리아에서 증식할 때 필요한 DNA 요소(bacterial DNA element)만을 가지고 있다(Spaete, R.R., and Frenkel, N. (1982). The herpes simplex virus amplicon: a new eukaryotic defective-virus cloning-amplifying vector. Cell 30, 295-304). 크기 제한이 있는 다른 바이러스 벡터와는 달리 HSV amplicon 바이 러스 vector는 150kb 의 DNA 까지도 바이러스 캡시드(viral capsid)안에 패키징(packaging)시킬 수 있어 large transgene capacity를 가지고 있으며, 플라스미드 내부에 바이러스 단백질을 만들 수 있는 유전자가 없기 때문에 ("gutted vector") 숙주세포에 독성을 나타내지 않는 장점이 있다. 또한 여러 종류의 세포에 유전자를 전달할 수 있는 능력도 있다. Herpes simplex virus amplicon plasmids (HSV amplicon plasmids) are propagated in bacteria and at least the viral DNA elements necessary for DNA replication origin (oriS) and virion DNA cleavage / packaging ( pac ). (Spaete, RR, and Frenkel, N. (1982) .The herpes simplex virus amplicon: a new eukaryotic defective-virus cloning-amplifying vector. Cell 30, 295-304. ). Unlike other viral vectors of limited size, the HSV amplicon virus vector can package up to 150kb of DNA into a viral capsid, which has a large transgene capacity and allows the production of viral proteins inside the plasmid. The absence of the gene ("gutted vector") has the advantage of not toxic to the host cell. It also has the ability to deliver genes to different types of cells.

최근에는 헤르페스 심플렉스 바이러스 제작 시 조금씩 오염되어 세포 독성을 유발할 가능성이 있었던 defective Herpes simplex 나 adeno helper-virus 없이 HSV amplicon plasmid vector를 바이러스 캡시드에 패키징할 수 있는 시스템 즉, 헬퍼 바이러스의 오염 가능성을 없앤 시스템이 개발된 바 있다(raefel, C., Song, S., Lim, F., Lang, P., Yu, L., Wang, Y., Wild, P., and Geller, A.I. (1996). Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. Journal of virology 70, 7190-7197; Saeki, Y., Fraefel, C., Ichikawa, T., Breakefield, X.O., and Chiocca, E.A. (2001). Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 3, 591-601; Saeki, Y., Ichikawa, T., Saeki, A., Chiocca, E.A., Tobler, K., Ackermann, M., Breakefield, X.O., and Fraefel, C. (1998). Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Human gene therapy 9, 2787-2794; Stavropoulos, T.A., and Strathdee, C.A. (1998). An enhanced packaging system for helper-dependent herpes simplex virus vectors. Journal of virology 72, 7137-7143).In recent years, HSV amplicon plasmid vector can be packaged in the virus capsid without defective Herpes simplex or adeno helper-virus, which is a little contaminated during the production of herpes simplex virus. Raefel, C., Song, S., Lim, F., Lang, P., Yu, L., Wang, Y., Wild, P., and Geller, AI (1996). virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells.Journal of virology 70, 7190-7197; Saeki, Y., Fraefel, C., Ichikawa, T., Breakefield, XO, and Chiocca, EA (2001 Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome.Mol Ther 3, 591-601; Saeki, Y., Ichikawa, T., Saeki, A., Chiocca, EA, Tobler, K., Ackermann, M., Breakefield, XO, and Fraefel, C. (1998) .Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors.Human gene therapy 9, 2787-2794; Stavropoulos, T.A., and Strathdee, C.A. (1998). An enhanced packaging system for helper-dependent herpes simplex virus vectors. Journal of virology 72, 7137-7143.

한편, 종래의 바이러스 벡터 시스템을 이용하여 두 개 이상의 유전자 발현 유닛(gene expression unit)을 한 개의 바이러스 [즉, 바이러스 입자(viral particle)] 내에 도입하고자 할 경우, 하나의 HSV amplicon plasmid 안에 두 개 이상의 유전자들을 발현하는 발현 유닛(프로모터-1개 유전자-polyA 의 발현 카세트가 2개 이상 혹은 IRES를 이용하여 한 개의 프러모터에 의해 두개의 유전자들이 발현되도록 만든 카세트)을 별도로 제작하여 바이러스에 도입하여야 한다. 그러나 이 경우, 플라스미드 즉 발현 유닛의 크기가 커지면 접합(ligation)이 어려워져 제작이 곤란할 뿐만 아니라, 여러 조합으로 유전자를 전달할 때 그 유전자 조합에 따라 각 조합의 유전자 구조체를 각각 별도로 제작하여야 하는 문제가 있다.Meanwhile, when introducing two or more gene expression units into one virus (ie, a viral particle) using a conventional viral vector system, two or more genes within one HSV amplicon plasmid Expression units expressing genes (either a cassette or a cassette in which two genes are expressed by one promoter using IRES using two or more expression cassettes of promoter-1 gene-polyA) should be separately introduced into the virus. . However, in this case, when the size of the plasmid, i.e., the expression unit, increases, the ligation becomes difficult, and production is difficult, and when the genes are transferred in various combinations, the gene structure of each combination must be separately produced according to the gene combinations. have.

본 발명자들은 HSV amplicon plasmid vector를 사용하여 2 이상의 유전자를 하나의 세포에 동시에 전달할 수 있는 방법을 개발하고자 다양한 연구를 수행하였다. 그 결과, 각각의 표적 유전자를 발현하는 앰플리콘 플라스미드를 두 개 이상 섞어 이들을 헬퍼 BAC DNA 와 pEBHICP27 플라스미드와 함께 수용세포(permissive cell line)에 동시-형질도입(co-transfection)시켜 패키징 시켰을 때, 놀랍게도 각각의 다른 앰플리콘 플라스미드 상에 존재하는 표적 유전자들이 동시에 하나의 바이러스 내에 패키징 될 수 있다는 것을 발견하였다. 이는, 두 개 이상의 앰플리콘 플라스미드들을 패키징하여 바이러스를 제조하더라도 rolling-circle mechanism에 의해서 한 종류의 앰플리콘 플라스미드만이 연쇄상으로(concatenate) 도입되게 된다는(도 2 참조) 기존의 학설만으로는 설명할 수 없는 새로운 발견이다.The present inventors conducted various studies to develop a method for simultaneously delivering two or more genes to a single cell using the HSV amplicon plasmid vector. As a result, when two or more amplicon plasmids expressing each target gene are mixed and co-transfected into the permissive cell line with helper BAC DNA and pEBHICP27 plasmid, they are surprisingly surprising. It was found that target genes present on each other amplicon plasmid can be packaged in one virus at the same time. This can not be explained by the existing theory that even if two or more amplicon plasmids are packaged to produce a virus, only one type of amplicon plasmid is concatenated by a rolling-circle mechanism (see FIG. 2). It is a new discovery.

따라서, 본 발명은 각각의 표적 유전자를 포함하는 앰플리콘 플라스미드들을 수용 세포 내에 동시-형질도입 시켜 패키징 시키는 단계를 포함하는, 즉 2 종 이상의 표적 유전자를 동시에 함유하는 바이러스를 쉽게 제조하는 방법을 제공하는 것을 목적으로 한다.Accordingly, the present invention provides a method for easily preparing a virus comprising simultaneously packaging amplicon plasmids containing each target gene into recipient cells, i.e., simultaneously containing two or more target genes. For the purpose of

본 발명의 일 태양에 따라, 2 종 이상의 표적 유전자를 각각 별도의 헤르페스 심플렉스 바이러스 앰플리콘 플라스미드(Herpes simplex virus amplicon plasmid)에 재조합시켜 얻어진 2 종 이상의 재조합 플라스미드를, fHSV△pac△27 0+ 및 pEBHICP27과 함께 수용 세포에 공동-형질도입 시켜 패키징(packaging)시키는 단계를 포함하는, 2 종 이상의 표적 유전자를 동시에 함유하는 바이러스를 간편하게 제조할 수 있는 방법이 제공된다.According to one aspect of the present invention, two or more recombinant plasmids obtained by recombining two or more target genes into a separate herpes simplex virus amplicon plasmid, respectively, include fHSVΔpacΔ27 0+ and Provided is a method for the convenient production of a virus containing two or more target genes simultaneously, comprising co-transduction and packaging of the recipient cells with pEBHICP27.

상기 헤르페스 심플렉스 바이러스 앰플리콘 플라스미드는 서열번호 1의 염기서열을 가질 수 있으며, 상기 표적 유전자들은 2 종 이상의 역분화 유도 유전자들일 수 있고, 예를 들어 서열번호 2 내지 7의 유전자로부터 2 종 이상 선택될 수 있다.The herpes simplex virus amplicon plasmid may have a nucleotide sequence of SEQ ID NO: 1, the target genes may be two or more reverse differentiation inducing genes, for example two or more selected from the genes of SEQ ID NOs: 2-7 Can be.

본 발명에 의해, 표적 유전자가 재조합된 재조합 플라스미드를 fHSV△pac△27 0+ 및 pEBHICP27와 함께 수용 세포에 공동-형질도입시켜 패키징함에 있어서, 상기 재조합 플라스미드가 2 종 이상일 경우 즉 2 종 이상의 재조합 플라스미드 존재 하에서 패키징을 수행할 경우, 각각의 재조합 플라스미드에 함유된 표적 유전자들이 동시에 바이러스에 도입된다는 것이 발견되었다. 이는, 두 개 이상의 앰플리콘 플라스미드들을 패키징하여 바이러스를 제조하더라도 rolling-circle mechanism 기작에 의해서 한 종류의 앰플리콘 플라스미드만이 연쇄상으로(concatenate) 바이러스 캡시드 안에 도입되게 된다는 기존의 설(도 2 참조)을 감안할 때, 매우 놀라운 것이다. 따라서, 본 발명의 바이러스 제조방법은 2 종 이상의 역분화 유도 인자를 코딩하는 유전자들이 도입된 바이러스 제조에 유용하게 사용될 수 있다.According to the present invention, in packaging the recombinant plasmid recombinant the target gene with fHSVΔpacΔ27 0+ and pEBHICP27 by co-transduction into a recipient cell, when the recombinant plasmid is two or more species, that is, two or more recombinant plasmids When packaging was performed in the presence, it was found that the target genes contained in each recombinant plasmid were simultaneously introduced into the virus. This suggests that even if a virus is produced by packaging two or more amplicon plasmids, only one amplicon plasmid is introduced into the viral capsid by a rolling-circle mechanism mechanism (see FIG. 2). Given that, it is very surprising. Therefore, the virus production method of the present invention can be usefully used for virus production in which genes encoding two or more kinds of reverse differentiation inducing factors are introduced.

본 발명은 2 종 이상의 표적 유전자를 각각 별도의 헤르페스 심플렉스 바이 러스 앰플리콘 플라스미드(Herpes simplex virus amplicon plasmid)에 재조합시켜 얻어진 2 종 이상의 재조합 플라스미드를, fHSV△pac△27 0+ 및 pEBHICP27과 함께 수용 세포에 공동-형질도입시켜 패키징(packaging)시키는 단계를 포함하는, 2 종 이상의 표적 유전자를 동시에 함유하는 헤르페스 심플렉스 바이러스 앰플리콘 바이러스의 제조방법을 제공한다.The present invention accommodates two or more recombinant plasmids obtained by recombining two or more target genes into separate herpes simplex virus amplicon plasmids together with fHSVΔpacΔ27 0+ and pEBHICP27. Provided is a method of preparing a herpes simplex virus amplicon virus simultaneously containing two or more target genes, the method comprising co-transduction and packaging into cells.

본 발명에 따른 제조방법은 2 종 이상의 표적유전자를 동시에 포함하는 헤르페스 심플렉스 바이러스를 제조하는데 있어서, Saeki et al. 이 개발한 무-헬퍼 바이러스 시스템(helper virus-free system)을 사용한다 (도 1 참조). 상기 시스템에서는 pac (packaging) 시그날을 제외한 전 HSV-1 게놈이 BAC (bacterial artificial chromosome)에 넣어져 있고 (fHSV△pac△27 0+), 안전성을 높이기 위해 ICP27 유전자를 BAC DNA에서 제거하여 또 다른 플라스미드인 pEBHICP27로서 제공해 준다. 이 세 종류의 플라스미드를 베로(vero) 2-2세포 등의 수용 세포(permissive cell line)에 공동-형질도입(co-transfection)해 주면 BAC DNA 와 pEBHICP27 플라스미드로부터 생산되는 HSV 입자 생성에 필요한 유전자 산물로 인하여 HSV particle의 구조가 만들어지고, 그 내부로 앰플리콘 DNA 가 HSV 캡시드(capsid)의 용량(capacity)인 150 kb 가 될 때까지 rolling circle mechanism에 의해 연쇄상으로(concatenate) 이어져 캡시드 내부를 채우게 된다(도 2 참조). 본 발명의 제조방법은 상기 Saeki et al. 등의 무-헬퍼 바이러스 시스템에 있어서, 2 종 이상의 앰플리콘 DNA 즉, 2 종 이상의 표적 유전자를 각각 별도의 헤르페스 심플렉스 바이러스 앰플리콘 플라스미드(Herpes simplex virus amplicon plasmid)에 재조합시켜 얻 어진 2 종 이상의 재조합 플라스미드를 공동-형질도입 시킬 경우, 2 종 이상의 표적 유전자를 동시에 함유하는 바이러스가 제조된다는 새로운 발견에 기초한다.The preparation method according to the present invention provides a method for preparing a herpes simplex virus comprising two or more target genes simultaneously, Saeki et al. The developed helper virus-free system is used (see FIG. 1). In this system, the entire HSV-1 genome, except for the pac (packaging) signal, is placed in a bacterial artificial chromosome (BAC) (fHSVΔpac △ 27 0+), and the ICP27 gene is removed from the BAC DNA for safety. It is provided as plasmid pEBHICP27. Co-transfection of these three plasmids into permissive cell lines, such as vero 2-2 cells, results in the gene products necessary for the production of HSV particles produced from BAC DNA and pEBHICP27 plasmids. Due to the structure of the HSV particles, the amplicon DNA is concatenated by the rolling circle mechanism to fill the capsid until the amplicon DNA reaches 150 kb, which is the capacity of the HSV capsid. (See Figure 2). The production method of the present invention is described in Saeki et al. In a non-helper virus system such as two or more amplicon DNAs, that is, two or more kinds of recombination obtained by recombining two or more target genes into a separate Herpes simplex virus amplicon plasmid, respectively. Co-transduction of the plasmids is based on new findings that viruses are produced that contain two or more target genes simultaneously.

본 발명의 제조방법에 있어서, 상기 표적 유전자는 특별히 제한된 것이 아니며, 바이러스 를 매개체로 통하여 숙주 세포에 도입하고자 하는 모든 유전자를 포함한다. 바람직하게는 분화된 세포의 재프로그램화에 관여하는 역분화 유도 인자(reprogramming-inducing factor)를 코딩하는 유전자가 포함된다. 상기 역분화 유도 인자는 기존에 밝혀져 있는 역분화 인자 즉, Sox2, Oct3/4, Nanog, Klf4, Lin28, 또는 Myc를 코딩하는 유전자일 수 있으며, 이들은 각각 서열번호 2 내지 7의 염기 서열을 갖는다. 당업자는 상기한 Sox2, Oct3/4, Nanog, Klf4, Lin28, c-Myc 뿐만 아니라, 역분화 유도에 관여하는 것으로 알려지거나 알려질 다양한 인자들이 본 발명에 따른 제조방법에 제한 없이 적용될 수 있음을 인식할 것이다. In the production method of the present invention, the target gene is not particularly limited, and includes all genes to be introduced into a host cell through a virus as a medium. Preferably, genes encoding reprogramming-inducing factors involved in reprogramming of differentiated cells are included. The reverse differentiation inducing factor may be a gene encoding the previously known reverse differentiation factor, that is, Sox2, Oct3 / 4, Nanog, Klf4, Lin28, or Myc, each having a nucleotide sequence of SEQ ID NOs: 2-7. Those skilled in the art will recognize that various factors known or known to be involved in inducing differentiation, as well as Sox2, Oct3 / 4, Nanog, Klf4, Lin28, c-Myc described above, can be applied without limitation to the preparation method according to the present invention. will be.

상기 재조합 플라스미드는 2 종 이상의 표적 유전자를 각각 별도의 헤르페스 심플렉스 바이러스 앰플리콘 플라스미드, 바람직하게는 더 서열번호 1의 염기서열을 갖는 헤르페스 심플렉스 바이러스 앰플리콘 플라스미드에 재조합시켜 얻어질 수 있다. 상기 재조합은 NheI, NotI, BamHI, BglII, XbaI 및 EcoRI 등의 적절한 제한효소를 사용하여 통상의 유전공학적 방법으로 표적 유전자를 클로닝하여 수행할 수 있다. The recombinant plasmid may be obtained by recombining two or more target genes into a separate herpes simplex virus amplicon plasmid, preferably a herpes simplex virus amplicon plasmid having a nucleotide sequence of SEQ ID NO: 1. The recombination may be performed by cloning the target gene by conventional genetic engineering methods using appropriate restriction enzymes such as NheI, NotI, BamHI, BglII, XbaI and EcoRI.

이하, 본 발명을 실시예를 통하여 더욱 상세히 설명한다. 그러나 이들 실시 예는 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrating the present invention, the scope of the present invention is not limited to these examples.

실시예Example

모델 유전자로서 GFP(green fluorescence protein)을 코딩하는 유전자(서열번호 8) 및 DsRed2(red fluorescence protein)를 코딩하는 유전자(서열번호 9)를 선정하였다.As a model gene, a gene encoding GFP (green fluorescence protein) (SEQ ID NO: 8) and a gene encoding DsRed2 (red fluorescence protein) (SEQ ID NO: 9) were selected.

헤르페스 심플레스 앰플리콘 플라스미드인 pHGCX(Saeki, Y., Fraefel, C., Ichikawa, T., Breakefield, X.O., and Chiocca, E.A. (2001). Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 3, 591-601) 내에는 GFP를 코딩하는 유전자가 헤르페스 심플렉스 바이러스 immediate early 프로모터 (IE4/5 promoter) 뒤에 이미 붙어 있기 때문에 그 자체로 GFP를 발현하는 재조합 플라스미드로 사용하였다. PHGCX, a herpes simplex amplicon plasmid (Saeki, Y., Fraefel, C., Ichikawa, T., Breakefield, XO, and Chiocca, EA (2001) .Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27 -deleted, oversized HSV-1 DNA in a bacterial artificial chromosome.In Mol Ther 3, 591-601, the gene encoding GFP is already attached after the herpes simplex virus immediate early promoter (IE4 / 5 promoter). As a recombinant plasmid expressing GFP.

pHGCX를 NruI과 NotI 제한효소의 이중처리로 GFP를 잘라낸 뒤 CIP (calf intestinal alkaline phosphatase) 처리를 하여 벡터를 제작하였다. 그 다음 pDsRed2 (Invitrogen) 상의 DsRed2 유전자를 SmaI 과 NotI 제한효소의 이중처리로 잘라내어 만들어진 벡터와 라이게이션(ligation)시켜 DsRed2 를 코딩하는 유전자가 헤르페스 심플렉스 바이러스 immediate early 프러모터 (IE4/5 promoter) 뒤에 위치하는 재조합 플라스미드(pHSVamp-DsRed2)를 제작하였다.pHGCX was cut out of GFP by double treatment of NruI and NotI restriction enzymes, and vector was prepared by CIP (calf intestinal alkaline phosphatase) treatment. The DsRed2 gene on pDsRed2 (Invitrogen) was then ligated with a vector cut and digested with SmaI and NotI restriction enzymes to encode DsRed2 followed by the herpes simplex virus immediate early promoter (IE4 / 5 promoter). Located recombinant plasmid (pHSVamp-DsRed2) was constructed.

상기에서 얻어진 두 개의 플라스미드들을 혼합하여 Saeki, Y. 등의 방법(Saeki, Y., Fraefel, C., Ichikawa, T., Breakefield, X.O., and Chiocca, E.A. (2001). Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 3, 591-601)을 변형하여, 베로 2-2 세포 (vero 2-2 cell: African green monkey kidney cell; from Dr. Rozanne Sandri-Goldin,. University of California, Irvine, CA, USA)에 공동-형질도입시켜 패키징을 수행하였다. 즉, 60 mm 세포배양 용기에 pHGCX(0.116 ug), pHSVamp-DsRed2(1.392 ug), pEBHICP27(0.07 ug) 및 helper-BAC DNA (fHSV△PAC△27 0+; 0.698 ug)를 섞어서 FugeneHD 8:2 로 Opti-MEM으로 같이 섞은 후 상온에서 15 분 후 베로 2-2 세포 위에 골고루 떨어뜨려 주었다. 37 ℃에서 4시간 동안 세포배양한 뒤 3 ml의 6% FBS로 보충된 DMEM을 넣어주고 60시간동안 HSV 앰플리콘 바이러스가 만들어 지도록 하였다. 세포 scraper로 세포들을 긁어모은 뒤 드라이아이스/에탄올 수욕(bath) 및 37 ℃의 수욕(water bath)에서 3번 얼렸다 녹였다 하면서, 세포 내에 있는 HSV 앰플리콘 바이러스들이 배지로 방출되도록 하였다. 배양액을 2000 x g로 원심분리하여 세포 침전물을 제외한 상층액을 얻었다. 이렇게 배지 내에 얻어진 바이러스를 인간 glioblastoma 세포주인 G16-9 세포(인간 글리오블라스토마, glioblastoma; Gli36 derived cell line tnat express HSV-1 VP 16 constitutuvely; widely available from many labs)에 감염시킨 후 2-3일 후에 형광단백질들 (GFP 및 DsRed2)을 발현하는 세포들의 수를 측정하였다. 그 결과는 도 3과 같다. 도 3에서 알 수 있는 바와 같이, 본 발명에 따른 제조방법으로 제조된 바이러스로 감염된 세포의 약 80% 정도가 GFP와 DsRed2 를 하나의 세포 안에 공통적으로 발현함을 알 수 있다.Saeki, Y. et al. (Saeki, Y., Fraefel, C., Ichikawa, T., Breakefield, XO, and Chiocca, EA (2001). system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome.Mol Ther 3, 591-601, modified to produce Vero 2-2 cells: African green monkey kidney packaging was performed co-transformed into cells; from Dr. Rozanne Sandri-Goldin, University of California, Irvine, CA, USA. That is, in a 60 mm cell culture container, pHGCX (0.116 ug), pHSVamp-DsRed2 (1.392 ug), pEBHICP27 (0.07 ug), and helper-BAC DNA (fHSVΔPACΔ27 0+; 0.698 ug) were mixed and FugeneHD 8: 2 After mixing together with Opti-MEM after 15 minutes at room temperature was evenly dropped on Vero 2-2 cells. After incubating the cells for 4 hours at 37 ° C, DMEM supplemented with 3 ml of 6% FBS was added and allowed to produce HSV amplicon virus for 60 hours. Cell scrapers were used to scrape the cells and freeze and thaw three times in a dry ice / ethanol bath and a water bath at 37 ° C., allowing the HSV amplicon viruses in the cells to be released into the medium. The culture was centrifuged at 2000 x g to obtain supernatant except cell precipitate. 2-3 days after the virus obtained in the medium was infected with G16-9 cells (human glioblastoma; Glioblastoma; Gli36 derived cell line tnat express HSV-1 VP 16 constitutuvely; widely available from many labs) The number of cells expressing fluorescent proteins (GFP and DsRed2) was then measured. The result is shown in FIG. 3. As can be seen in Figure 3, it can be seen that about 80% of cells infected with the virus prepared by the production method according to the present invention commonly express GFP and DsRed2 in one cell.

비교예 Comparative example

실시예 1에서 얻어진 GFP를 발현하는 재조합 플라스미드 및 DsRed2를 발현하는 재조합 플라스미드를 각각 별도로 실시예 1과 동일한 방법으로 패키징하고, 얻어진 바이러스 각각을 혼합하여 G16-9 세포에 감염시켜 형광단백질들 (GFP 및 DsRed2)의 발현을 측정하였다. 그 결과는 도 4와 같다. 도 4에서 알 수 있는 바와 같이, 약 2.6% 정도의 세포들만이 GFP와 DsRed2를 한 세포 안에 공통적으로 발현됨을 알 수 있다.The recombinant plasmid expressing GFP and the recombinant plasmid expressing DsRed2 obtained in Example 1 were separately packaged in the same manner as in Example 1, and the obtained viruses were mixed and infected with G16-9 cells to fluorescein proteins (GFP and DsRed2) expression was measured. The result is shown in FIG. 4. As can be seen in Figure 4, only about 2.6% of cells can be seen that the common expression of GFP and DsRed2 in one cell.

도 1은 fHSV△pac△27 0+ 및 pEBHICP27 시스템을 이용한 무-헬퍼 바이러스 시스템을 통해 앰플리콘 벡터를 제작하는 과정을 나타내는 모식도이다.FIG. 1 is a schematic diagram illustrating a process for preparing an amplicon vector through a virus-free helper system using fHSVΔpacΔ27 0+ and pEBHICP27 system.

도 2는 종래의 패키징 방법으로서 앰플리콘 플라스미드가 rolling circle mechanism 에 의해 연쇄상으로(concatenate) 여러 카피가 이어져 앰플리콘 벡터가 제작되는 과정을 나타내는 모식도이다.FIG. 2 is a schematic diagram illustrating a process in which an amplicon vector is produced by concatenating multiple copies of an amplicon plasmid concatenate by a rolling circle mechanism as a conventional packaging method.

도 3 은 각각 GFP와 DsRed2를 발현하는 유닛을 가진 두 종류의 다른 앰플리콘 플라스미드를 BAC DNA 와 pEBHICP27 와 함께 공동-형질도입(co-transfection)하여 얻어진 바이러스를 G16-9 세포에 감염시켜 GFP 및 DsRed2를 공동 발현하는 세포가 전체 세포에서 차지하는 비율을 측정한 결과를 나타낸다(*P= 0.00042; #P= 0.00242).FIG. 3 shows that GFP-9 and DsRed2 are infected with G16-9 cells by infecting G16-9 cells with a virus obtained by co-transfection of two different amplicon plasmids with units expressing GFP and DsRed2, respectively, together with BAC DNA and pEBHICP27. Indicates the result of measuring the proportion of cells co-expressing in total cells (* P = 0.00042; # P = 0.00242).

도 4는 GFP와 DsRed2를 함유하는 앰플리콘 플라스미드로부터 각각 별도로 바이러스를 제작하고, 얻어진 GFP를 발현하는 바이러스와 DsRed2를 발현하는 바이러스를 함께 섞어서 G16-9 세포에 감염시켜 GFP 및/또는 DsRed2를 발현하는 세포의 비율을 측정한 결과를 나타낸다(*P= 0.00013; #P= 0.02).FIG. 4 shows that a virus is separately prepared from an amplicon plasmid containing GFP and DsRed2, mixed with a virus expressing GFP and a virus expressing DsRed2, and infected with G16-9 cells to express GFP and / or DsRed2. The result of measuring the ratio of cells is shown (* P = 0.00013; #P = 0.02).

<110> College of Medicine Pochon CHA University Industry-Academic Cooperation Foundation <120> Method for producing viruses co-packaged with two or more target genes <130> PN0181 <160> 9 <170> KopatentIn 1.71 <210> 1 <211> 6723 <212> DNA <213> herpes simplex virus 7 <400> 1 ggcagtacat caatgggcgt ggatagcggt ttgactcacg gggatttcca agtctccacc 60 ccattgacgt caatgggagt ttgttttggc accaaaatca acgggacttt ccaaaatgtc 120 gtaacaactc cgccccattg acgcaaatgg gcggtaggcg tgtacggtgg gaggtctata 180 taagcagagc tctctggcta actagagaac ccactgctta ctggcttatc gaaattaata 240 cgactcacta tagggagacc caagctggct agcgtttaaa cttaagcttg gtaccgagct 300 cggatccact agtccagtgt ggtggaattc tgcagatatc cagcacagtg gcggccgctc 360 gagtctagag ggcccgttta aacccgctga tcagcctcga ctgtgccttc tagttgccag 420 ccatctgttg tttgcccctc ccccgtgcct tccttgaccc tggaaggtgc cactcccact 480 gtcctttcct aataaaatga ggaaattgca tcgcattgtc tgagtaggtg tcattctatt 540 ctggggggtg gggtggggca ggacagcaag ggggaggatt gggaagacaa tagcgttaat 600 taaaattcca gctgagcgcc ggtcgctacc attaccagtt ggtctggtgt caaaaataat 660 aataaccggg caggccatgt ctgcccgtat ttcgcgtaag gaaatccatt atgtactatt 720 taaaaaacac aaacttttgg atgttcggtt tattcttttt cttttacttt tttatcatgg 780 gagcctactt cccgtttttc ccgatttggc tacatgacat caaccatatc agcaaaagtg 840 atacgggtat tatttttgcc gctatttctc tgttctcgct attattccaa ccgctgtttg 900 gtctgctttc tgacaaactc ggaacttgtt tattgcagct tataatggtt acaaataaag 960 caatagcatc acaaatttca caaataaagc atttttttca ctgcattcta gttgtggttg 1020 tccaaactca tcaatgtatc ttatcatgtc tggatctctg acctgagatt ggcggcactg 1080 aggtagagat gcccgaaccc ccccgaggga gcgcgggacg cgccggggag ggctggggcc 1140 ggggagggct ggggccgggg agggctgggg ccggggaggg ctggggccgg ggagggctgg 1200 ggccggggag ggctggggcc ggggagggct ggggctgggg agggctgggg ctggggaggg 1260 ggcggtggtg tgtagcagga gcggtgtgtt gcgccggggt acgtctggag gagcgggagg 1320 tgcgcggtga cgtgtggatg aggaacagga gttgttgcgc ggtgagttgt cgctgtgagt 1380 tgtgttgttg ggcaggtgtg gtggatgacg tgacgtgtga cgtgcggagt gcgccgtgct 1440 ctgttggttt cacctgtggc agcccgggcc ccccgcgggc gcgcgcgcgc gcaaaaaagg 1500 cgggcggcgg tccgggcggc gtgcgcgcgc gcggcgggcg tggggggcgg ggccgcggga 1560 gcggggggag gagcgggggg aggagcgggg ggaggagcgg ggggaggagc ggggggagga 1620 gcggggggag gagcgggggg aggagcgggg ggaggagcgg ggggaggagc ggggggagga 1680 gcggggggag gagcgggggg aggagcgggg ggaggagcgg ggggaggagc ggggggagga 1740 gcggggggag gagcgggggg aggagcgggg ggaggagcgg ccagacgccg aaaacgggcc 1800 ccccccaaaa cacacccccc gggggtcgcg cgcggccctt taaagcggtg gcggcgggca 1860 gcccgggccc cccgcggccg agactagcga gttagacagg caagcactac tcgcctctgc 1920 acgcacatgc ttgcctgtca aactctacca ccccggcacg ctctctgtct ccatggcccg 1980 ccgccgccgc catcgcggcc cccgccgccc ccggccgccc gggcccacgg gcgccgtccc 2040 aaccgcacag tcccaggtaa cgagctcgaa ttaattcttg aagacgaaag ggcctcgtga 2100 tacgcctatt tttataggtt aatgtcatga taataatggt ttcttagggt cgacccaggt 2160 ggcacttttc ggggaaatgt gcgcggaacc cctatttgtt tatttttcta aatacattca 2220 aatatgtatc cgctcatgag acaataaccc tgataaatgc ttcaataata ttgaaaaagg 2280 aagagtatga gtattcaaca tttccgtgtc gcccttattc ccttttttgc ggcattttgc 2340 cttcctgttt ttgctcaccc agaaacgctg gtgaaagtaa aagatgctga agatcagttg 2400 ggtgcacgag tgggttacat cgaactggat ctcaacagcg gtaagatcct tgagagtttt 2460 cgccccgaag aacgttttcc aatgatgagc acttttaaag ttctgctatg tggcgcggta 2520 ttatcccgtg ttgacgccgg gcaagagcaa ctcggtcgcc gcatacacta ttctcagaat 2580 gacttggttg agtactcacc agtcacagaa aagcatctta cggatggcat gacagtaaga 2640 gaattatgca gtgctgccat aaccatgagt gataacactg cggccaactt acttctgaca 2700 acgatcggag gaccgaagga gctaaccgct tttttgcaca acatggggga tcatgtaact 2760 cgccttgatc gttgggaacc ggagctgaat gaagccatac caaacgacga gcgtgacacc 2820 acgatgcctg cagcaatggc aacaacgttg cgcaaactat taactggcga actacttact 2880 ctagcttccc ggcaacaatt aatagactgg atggaggcgg ataaagttgc aggaccactt 2940 ctgcgctcgg cccttccggc tggctggttt attgctgata aatctggagc cggtgagcgt 3000 gggtctcgcg gtatcattgc agcactgggg ccagatggta agccctcccg tatcgtagtt 3060 atctacacga cggggagtca ggcaactatg gatgaacgaa atagacagat cgctgagata 3120 ggtgcctcac tgattaagca ttggtaactg tcagaccaag tttactcata tatactttag 3180 attgatttaa aacttcattt ttaatttaaa aggatctagg tgaagatcct ttttgataat 3240 ctcatgacca aaatccctta acgtgagttt tcgttccact gagcgtcaga ccccgtagaa 3300 aagatcaaag gatcttcttg agatcctttt tttctgcgcg taatctgctg cttgcaaaca 3360 aaaaaaccac cgctaccagc ggtggtttgt ttgccggatc aagagctacc aactcttttt 3420 ccgaaggtaa ctggcttcag cagagcgcag ataccaaata ctgtccttct agtgtagccg 3480 tagttaggcc accacttcaa gaactctgta gcaccgccta catacctcgc tctgctaatc 3540 ctgttaccag tggctgctgc cagtggcgat aagtcgtgtc ttaccgggtt ggactcaaga 3600 cgatagttac cggataaggc gcagcggtcg ggctgaacgg ggggttcgtg cacacagccc 3660 agcttggagc gaacgaccta caccgaactg agatacctac agcgtgagct atgagaaagc 3720 gccacgcttc ccgaagggag aaaggcggac aggtatccgg taagcggcag ggtcggaaca 3780 ggagagcgca cgagggagct tccaggggga aacgcctggt atctttatag tcctgtcggg 3840 tttcgccacc tctgacttga gcgtcgattt ttgtgatgct cgtcaggggg gcggagccta 3900 tggaaaaacg ccagcaacgc ggccttttta cggttcctgg ccttttgctg gccttttgct 3960 cacatgttct ttcctgcgtt atcccctgat tctgtggata accgtattac cgcctttgag 4020 tgagctgata ccgctcgccg cagccgaacg accgagcgca gcgagtcagt gagcgaggaa 4080 gcggaagagc gcctgatgcg gtattttctc cttacgcatc tgtgcggtat ttcacaccgc 4140 ataggtcgac ctatggtgca ctctcagtac aatctgctct gatgccgcat agttaagcca 4200 gtatacactc cgctatcgct acgtgactgg gtcatggctg cgccccgaca cccgccaaca 4260 cccgctgacg cgccctgacg ggcttgtctg ctcccggcat ccgcttacag acaagctgtg 4320 accgtctccg ggagctgcat gtgtcagagg ttttcaccgt catcaccgaa acgcgcgagg 4380 cagccggcca ttatgcacga ccccgccccg acgccggcac gccgggggcc cgtggccgcg 4440 gcccgttggt cgaacccccg gccccgccca tccgcgccat ctgccatggg cggggcgcga 4500 gggcgggtgg gtccgcgccc cgccccgcat ggcatctcat taccgcccga tccggcggtt 4560 tccgcttccg ttccgcatgc taacgaggaa cgggcagggg gcggggcccg ggccccgact 4620 tcccggttcg gcggtaatga gatacgagcc ccgcgcgccc gttggccgtc cccgggcccc 4680 ccggtcccgc ccgccggacg ccgggaccaa cgggacggcg ggcggcccaa gggccgcccg 4740 ccttgccgcc cccccattgg ccggcgggcg ggaccgcccc aagggggcgg ggccgccggg 4800 taaaagaagt gagaacgcga agcgttcgca cttcgtccca atatatatat attattaggg 4860 cgaagtgcga gcactggcgc cgtgcccgac tccgcgccgg ccccgggggc gggcccgggc 4920 ggcggggggc gggtctctcc ggcgcacata aaggcccggc gcgaccgacg cccgcagacg 4980 gcgccggcca cgaacgacgg gagcggctgc ggagcacgcg gaccgggagc gggagtcgca 5040 gagggccgtc ggagcggacg gcgtcggcat cgcgacgccc cggctcggga tcgggatcgc 5100 atcggaaagg gacacgcgga cgcggggggg aaagacccgc ccaccccacc cacgaaacac 5160 aggggacgca ccccgggggc ctccgacgac agaaacccac cggtccgcct tttttgcacg 5220 ggtaagcacc ttgggtgggc ggaggagggg gggacgcggg ggtggaggag gggggacgcg 5280 ggggcggagg aggggggacg cgggggcgga ggagggggga cgcgggggcg gaggaggggg 5340 gacgcggggg cggaggaggg ggctcacccg cgttcgtgcc ttcccgcagg aggaacgtcc 5400 tcgtcgataa gctgatccat cgccaccatg gtgagcaagg gcgaggagct gttcaccggg 5460 gtggtgccca tcctggtcga gctggacggc gacgtaaacg gccacaagtt cagcgtgtcc 5520 ggcgagggcg agggcgatgc cacctacggc aagctgaccc tgaagttcat ctgcaccacc 5580 ggcaagctgc ccgtgccctg gcccaccctc gtgaccaccc tgacctacgg cgtgcagtgc 5640 ttcagccgct accccgacca catgaagcag cacgacttct tcaagtccgc catgcccgaa 5700 ggctacgtcc aggagcgcac catcttcttc aaggacgacg gcaactacaa gacccgcgcc 5760 gaggtgaagt tcgagggcga caccctggtg aaccgcatcg agctgaaggg catcgacttc 5820 aaggaggacg gcaacatcct ggggcacaag ctggagtaca actacaacag ccacaacgtc 5880 tatatcatgg ccgacaagca gaagaacggc atcaaggtga acttcaagat ccgccacaac 5940 atcgaggacg gcagcgtgca gctcgccgac cactaccagc agaacacccc catcggcgac 6000 ggccccgtgc tgctgcccga caaccactac ctgagcaccc agtccgccct gagcaaagac 6060 cccaacgaga agcgcgatca catggtcctg ctggagttcg tgaccgccgc cgggatcact 6120 ctcggcatgg acgagctgta caagtaaagc ggccaacttg tttattgcag cttataatgg 6180 ttacaaataa agcaatagca tcacaaattt cacaaataaa gcattttttt cactgcattc 6240 tagttgtggt ttgtccaaac tcatcaatgt atcttatcat gtctggatcg gtttgaagat 6300 cttccgatgt acgggccaga tatacgcgtt gacattgatt attgactagt tattaatagt 6360 aatcaattac ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta 6420 cggtaaatgg cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga 6480 cgtatgttcc catagtaacg ccaataggga ctttccattg acgtcaatgg gtggactatt 6540 tacggtaaac tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgcccccta 6600 ttgacgtcaa tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg 6660 actttcctac ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt 6720 ttt 6723 <210> 2 <211> 954 <212> DNA <213> Homo sapiens <400> 2 atgtacaaca tgatggagac ggagctgaag ccgccgggcc cgcagcaaac ttcggggggc 60 ggcggcggca actccaccgc ggcggcggcc ggcggcaacc agaaaaacag cccggaccgc 120 gtcaagcggc ccatgaatgc cttcatggtg tggtcccgcg ggcagcggcg caagatggcc 180 caggagaacc ccaagatgca caactcggag atcagcaagc gcctgggcgc cgagtggaaa 240 cttttgtcgg agacggagaa gcggccgttc atcgacgagg ctaagcggct gcgagcgctg 300 cacatgaagg agcacccgga ttataaatac cggccccggc ggaaaaccaa gacgctcatg 360 aagaaggata agtacacgct gcccggcggg ctgctggccc ccggcggcaa tagcatggcg 420 agcggggtcg gggtgggcgc cggcctgggc gcgggcgtga accagcgcat ggacagttac 480 gcgcacatga acggctggag caacggcagc tacagcatga tgcaggacca gctgggctac 540 ccgcagcacc cgggcctcaa tgcgcacggc gcagcgcaga tgcagcccat gcaccgctac 600 gacgtgagcg ccctgcagta caactccatg accagctcgc agacctacat gaacggctcg 660 cccacctaca gcatgtccta ctcgcagcag ggcacccctg gcatggctct tggctccatg 720 ggttcggtgg tcaagtccga ggccagctcc agcccccctg tggttacctc ttcctcccac 780 tccagggcgc cctgccaggc cggggacctc cgggacatga tcagcatgta tctccccggc 840 gccgaggtgc cggaacccgc cgcccccagc agacttcaca tgtcccagca ctaccagagc 900 ggcccggtgc ccggcacggc cattaacggc acactgcccc tctcacacat gtga 954 <210> 3 <211> 1083 <212> DNA <213> Homo sapiens <400> 3 atggcgggac acctggcttc ggatttcgcc ttctcgcccc ctccaggtgg tggaggtgat 60 gggccagggg ggccggagcc gggctgggtt gatcctcgga cctggctaag cttccaaggc 120 cctcctggag ggccaggaat cgggccgggg gttgggccag gctctgaggt gtgggggatt 180 cccccatgcc ccccgccgta tgagttctgt ggggggatgg cgtactgtgg gccccaggtt 240 ggagtggggc tagtgcccca aggcggcttg gagacctctc agcctgaggg cgaagcagga 300 gtcggggtgg agagcaactc cgatggggcc tccccggagc cctgcaccgt cacccctggt 360 gccgtgaagc tggagaagga gaagctggag caaaacccgg aggagtccca ggacatcaaa 420 gctctgcaga aagaactcga gcaatttgcc aagctcctga agcagaagag gatcaccctg 480 ggatatacac aggccgatgt ggggctcacc ctgggggttc tatttgggaa ggtattcagc 540 caaacgacca tctgccgctt tgaggctctg cagcttagct tcaagaacat gtgtaagctg 600 cggcccttgc tgcagaagtg ggtggaggaa gctgacaaca atgaaaatct tcaggagata 660 tgcaaagcag aaaccctcgt gcaggcccga aagagaaagc gaaccagtat cgagaaccga 720 gtgagaggca acctggagaa tttgttcctg cagtgcccga aacccacact gcagcagatc 780 agccacatcg cccagcagct tgggctcgag aaggatgtgg tccgagtgtg gttctgtaac 840 cggcgccaga agggcaagcg atcaagcagc gactatgcac aacgagagga ttttgaggct 900 gctgggtctc ctttctcagg gggaccagtg tcctttcctc tggccccagg gccccatttt 960 ggtaccccag gctatgggag ccctcacttc actgcactgt actcctcggt ccctttccct 1020 gagggggaag cctttccccc tgtctccgtc accactctgg gctctcccat gcattcaaac 1080 tga 1083 <210> 4 <211> 918 <212> DNA <213> Homo sapiens <400> 4 atgagtgtgg atccagcttg tccccaaagc ttgccttgct ttgaagcatc cgactgtaaa 60 gaatcttcac ctatgcctgt gatttgtggg cctgaagaaa actatccatc cttgcaaatg 120 tcttctgctg agatgcctca cacggagact gtctctcctc ttccttcctc catggatctg 180 cttattcagg acagccctga ttcttccacc agtcccaaag gcaaacaacc cacttctgca 240 gagaagagtg tcgcaaaaaa ggaagacaag gtcccggtca agaaacagaa gaccagaact 300 gtgttctctt ccacccagct gtgtgtactc aatgatagat ttcagagaca gaaatacctc 360 agcctccagc agatgcaaga actctccaac atcctgaacc tcagctacaa acaggtgaag 420 acctggttcc agaaccagag aatgaaatct aagaggtggc agaaaaacaa ctggccgaag 480 aatagcaatg gtgtgacgca gaaggcctca gcacctacct accccagcct ttactcttcc 540 taccaccagg gatgcctggt gaacccgact gggaaccttc caatgtggag caaccagacc 600 tggaacaatt caacctggag caaccagacc cagaacatcc agtcctggag caaccactcc 660 tggaacactc agacctggtg cacccaatcc tggaacaatc aggcctggaa cagtcccttc 720 tataactgtg gagaggaatc tctgcagtcc tgcatgcagt tccagccaaa ttctcctgcc 780 agtgacttgg aggctgcctt ggaagctgct ggggaaggcc ttaatgtaat acagcagacc 840 actaggtatt ttagtactcc acaaaccatg gatttattcc taaactactc catgaacatg 900 caacctgaag acgtgtga 918 <210> 5 <211> 1440 <212> DNA <213> Homo sapiens <400> 5 atgaggcagc cacctggcga gtctgacatg gctgtcagcg acgcgctgct cccatctttc 60 tccacgttcg cgtctggccc ggcgggaagg gagaagacac tgcgtcaagc aggtgccccg 120 aataaccgct ggcgggagga gctctcccac atgaagcgac ttcccccagt gcttcccggc 180 cgcccctatg acctggcggc ggcgaccgtg gccacagacc tggagagcgg cggagccggt 240 gcggcttgcg gcggtagcaa cctggcgccc ctacctcgga gagagaccga ggagttcaac 300 gatctcctgg acctggactt tattctctcc aattcgctga cccatcctcc ggagtcagtg 360 gccgccaccg tgtcctcgtc agcgtcagcc tcctcttcgt cgtcgccgtc gagcagcggc 420 cctgccagcg cgccctccac ctgcagcttc acctatccga tccgggccgg gaacgacccg 480 ggcgtggcgc cgggcggcac gggcggaggc ctcctctatg gcagggagtc cgctccccct 540 ccgacggctc ccttcaacct ggcggacatc aacgacgtga gcccctcggg cggcttcgtg 600 gccgagctcc tgcggccaga attggacccg gtgtacattc cgccgcagca gccgcagccg 660 ccaggtggcg ggctgatggg caagttcgtg ctgaaggcgt cgctgagcgc ccctggcagc 720 gagtacggca gcccgtcggt catcagcgtc agcaaaggca gccctgacgg cagccacccg 780 gtggtggtgg cgccctacaa cggcgggccg ccgcgcacgt gccccaagat caagcaggag 840 gcggtctctt cgtgcaccca cttgggcgct ggaccccctc tcagcaatgg ccaccggccg 900 gctgcacacg acttccccct ggggcggcag ctccccagca ggactacccc gaccctgggt 960 cttgaggaag tgctgagcag cagggactgt caccctgccc tgccgcttcc tcccggcttc 1020 catccccacc cggggcccaa ttacccatcc ttcctgcccg atcagatgca gccgcaagtc 1080 ccgccgctcc attaccaaga gctcatgcca cccggttcct gcatgccaga ggagcccaag 1140 ccaaagaggg gaagacgatc gtggccccgg aaaaggaccg ccacccacac ttgtgattac 1200 gcgggctgcg gcaaaaccta cacaaagagt tcccatctca aggcacacct gcgaacccac 1260 acaggtgaga aaccttacca ctgtgactgg gacggctgtg gatggaaatt cgcccgctca 1320 gatgaactga ccaggcacta ccgtaaacac acggggcacc gcccgttcca gtgccaaaaa 1380 tgcgaccgag cattttccag gtcggaccac ctcgccttac acatgaagag gcatttttaa 1440 1440 <210> 6 <211> 630 <212> DNA <213> Homo sapiens <400> 6 atgggctccg tgtccaacca gcagtttgca ggtggctgcg ccaaggcggc agaagaggcg 60 cccgaggagg cgccggagga cgcggcccgg gcggcggacg agcctcagct gctgcacggt 120 gcgggcatct gtaagtggtt caacgtgcgc atggggttcg gcttcctgtc catgaccgcc 180 cgcgccgggg tcgcgctcga ccccccagtg gatgtctttg tgcaccagag taagctgcac 240 atggaagggt tccggagctt gaaggagggt gaggcagtgg agttcacctt taagaagtca 300 gccaagggtc tggaatccat ccgtgtcacc ggacctggtg gagtattctg tattgggagt 360 gagaggcggc caaaaggaaa gagcatgcag aagcgcagat caaaaggaga caggtgctac 420 aactgtggag gtctagatca tcatgccaag gaatgcaagc tgccacccca gcccaagaag 480 tgccacttct gccagagcat cagccatatg gtagcctcat gtccgctgaa ggcccagcag 540 ggccctagtg cacagggaaa gccaacctac tttcgagagg aagaagaaga aatccacagc 600 cctaccctgc tcccggaggc acagaattga 630 <210> 7 <211> 1365 <212> DNA <213> Homo sapiens <400> 7 ctggattttt ttcgggtagt ggaaaaccag cagcctcccg cgacgatgcc cctcaacgtt 60 agcttcacca acaggaacta tgacctcgac tacgactcgg tgcagccgta tttctactgc 120 gacgaggagg agaacttcta ccagcagcag cagcagagcg agctgcagcc cccggcgccc 180 agcgaggata tctggaagaa attcgagctg ctgcccaccc cgcccctgtc ccctagccgc 240 cgctccgggc tctgctcgcc ctcctacgtt gcggtcacac ccttctccct tcggggagac 300 aacgacggcg gtggcgggag cttctccacg gccgaccagc tggagatggt gaccgagctg 360 ctgggaggag acatggtgaa ccagagtttc atctgcgacc cggacgacga gaccttcatc 420 aaaaacatca tcatccagga ctgtatgtgg agcggcttct cggccgccgc caagctcgtc 480 tcagagaagc tggcctccta ccaggctgcg cgcaaagaca gcggcagccc gaaccccgcc 540 cgcggccaca gcgtctgctc cacctccagc ttgtacctgc aggatctgag cgccgccgcc 600 tcagagtgca tcgacccctc ggtggtcttc ccctaccctc tcaacgacag cagctcgccc 660 aagtcctgcg cctcgcaaga ctccagcgcc ttctctccgt cctcggattc tctgctctcc 720 tcgacggagt cctccccgca gggcagcccc gagcccctgg tgctccatga ggagacaccg 780 cccaccacca gcagcgactc tgaggaggaa caagaagatg aggaagaaat cgatgttgtt 840 tctgtggaaa agaggcaggc tcctggcaaa aggtcagagt ctggatcacc ttctgctgga 900 ggccacagca aacctcctca cagcccactg gtcctcaaga ggtgccacgt ctccacacat 960 cagcacaact acgcagcgcc tccctccact cggaaggact atcctgctgc caagagggtc 1020 aagttggaca gtgtcagagt cctgagacag atcagcaaca accgaaaatg caccagcccc 1080 aggtcctcgg acaccgagga gaatgtcaag aggcgaacac acaacgtctt ggagcgccag 1140 aggaggaacg agctaaaacg gagctttttt gccctgcgtg accagatccc ggagttggaa 1200 aacaatgaaa aggcccccaa ggtagttatc cttaaaaaag ccacagcata catcctgtcc 1260 gtccaagcag aggagcaaaa gctcatttct gaagaggact tgttgcggaa acgacgagaa 1320 cagttgaaac acaaacttga acagctacgg aactcttgtg cgtaa 1365 <210> 8 <211> 749 <212> DNA <213> Artificial Sequence <220> <223> Artificial sequence <400> 8 atggtgagca agggcgagga gctgttcacc ggggtggtgc ccatcctggt cgagctggac 60 ggcgacgtaa acggccacaa gttcagcgtg tccggcgagg gcgagggcga tgccacctac 120 ggcaagctga ccctgaagtt catctgcacc accggcaagc tgcccgtgcc ctggcccacc 180 ctcgtgacca ccctgaccta cggcgtgcag tgcttcagcc gctaccccga ccacatgaag 240 cagcacgact tcttcaagtc cgccatgccc gaaggctacg tccaggagcg caccatcttc 300 ttcaaggacg acggcaacta caagacccgc gccgaggtga agttcgaggg cgacaccctg 360 gtgaaccgca tcgagctgaa gggcatcgac ttcaaggagg acggcaacat cctggggcac 420 aagctggagt acaactacaa cagccacaac gtctatatca tggccgacaa gcagaagaac 480 ggcatcaagg tgaacttcaa gatccgccac aacatcgagg acggcagcgt gcagctcgcc 540 gaccactacc agcagaacac ccccatcggc gacggccccg tgctgctgcc cgacaaccac 600 tacctgagca cccagtccgc cctgagcaaa gaccccaacg agaagcgcga tcacatggtc 660 ctgctggagt tcgtgaccgc cgccgggatc actctcggca tggacgagct gtactaatga 720 ccccgtaatt gattactatt aataactaa 749 <210> 9 <211> 678 <212> DNA <213> Artificial Sequence <220> <223> Artificial sequence <400> 9 atggcctcct ccgagaacgt catcaccgag ttcatgcgct tcaaggtgcg catggagggc 60 accgtgaacg gccacgagtt cgagatcgag ggcgagggcg agggccgccc ctacgagggc 120 cacaacaccg tgaagctgaa ggtgaccaag ggcggccccc tgcccttcgc ctgggacatc 180 ctgtcccccc agttccagta cggctccaag gtgtacgtga agcaccccgc cgacatcccc 240 gactacaaga agctgtcctt ccccgagggc ttcaagtggg agcgcgtgat gaacttcgag 300 gacggcggcg tggcgaccgt gacccaggac tcctccctgc aggacggctg cttcatctac 360 aaggtgaagt tcatcggcgt gaacttcccc tccgacggcc ccgtgatgca gaagaagacc 420 atgggctggg aggcctccac cgagcgcctg tacccccgcg acggcgtgct gaagggcgag 480 acccacaagg ccctgaagct gaaggacggc ggccactacc tggtggagtt caagtccatc 540 tacatggcca agaagcccgt gcagctgccc ggctactact acgtggacgc caagctggac 600 atcacctccc acaacgagga ctacaccatc gtggagcagt acgagcgcac cgagggccgc 660 caccacctgt tcctgtag 678 <110> College of Medicine Pochon CHA University Industry-Academic Cooperation Foundation <120> Method for producing viruses co-packaged with two or more target          genes <130> PN0181 <160> 9 <170> KopatentIn 1.71 <210> 1 <211> 6723 <212> DNA <213> herpes simplex virus 7 <400> 1 ggcagtacat caatgggcgt ggatagcggt ttgactcacg gggatttcca agtctccacc 60 ccattgacgt caatgggagt ttgttttggc accaaaatca acgggacttt ccaaaatgtc 120 gtaacaactc cgccccattg acgcaaatgg gcggtaggcg tgtacggtgg gaggtctata 180 taagcagagc tctctggcta actagagaac ccactgctta ctggcttatc gaaattaata 240 cgactcacta tagggagacc caagctggct agcgtttaaa cttaagcttg gtaccgagct 300 cggatccact agtccagtgt ggtggaattc tgcagatatc cagcacagtg gcggccgctc 360 gagtctagag ggcccgttta aacccgctga tcagcctcga ctgtgccttc tagttgccag 420 ccatctgttg tttgcccctc ccccgtgcct tccttgaccc tggaaggtgc cactcccact 480 gtcctttcct aataaaatga ggaaattgca tcgcattgtc tgagtaggtg tcattctatt 540 ctggggggtg gggtggggca ggacagcaag ggggaggatt gggaagacaa tagcgttaat 600 taaaattcca gctgagcgcc ggtcgctacc attaccagtt ggtctggtgt caaaaataat 660 aataaccggg caggccatgt ctgcccgtat ttcgcgtaag gaaatccatt atgtactatt 720 taaaaaacac aaacttttgg atgttcggtt tattcttttt cttttacttt tttatcatgg 780 gagcctactt cccgtttttc ccgatttggc tacatgacat caaccatatc agcaaaagtg 840 atacgggtat tatttttgcc gctatttctc tgttctcgct attattccaa ccgctgtttg 900 gtctgctttc tgacaaactc ggaacttgtt tattgcagct tataatggtt acaaataaag 960 caatagcatc acaaatttca caaataaagc atttttttca ctgcattcta gttgtggttg 1020 tccaaactca tcaatgtatc ttatcatgtc tggatctctg acctgagatt ggcggcactg 1080 aggtagagat gcccgaaccc ccccgaggga gcgcgggacg cgccggggag ggctggggcc 1140 ggggagggct ggggccgggg agggctgggg ccggggaggg ctggggccgg ggagggctgg 1200 ggccggggag ggctggggcc ggggagggct ggggctgggg agggctgggg ctggggaggg 1260 ggcggtggtg tgtagcagga gcggtgtgtt gcgccggggt acgtctggag gagcgggagg 1320 tgcgcggtga cgtgtggatg aggaacagga gttgttgcgc ggtgagttgt cgctgtgagt 1380 tgtgttgttg ggcaggtgtg gtggatgacg tgacgtgtga cgtgcggagt gcgccgtgct 1440 ctgttggttt cacctgtggc agcccgggcc ccccgcgggc gcgcgcgcgc gcaaaaaagg 1500 cgggcggcgg tccgggcggc gtgcgcgcgc gcggcgggcg tggggggcgg ggccgcggga 1560 gcggggggag gagcgggggg aggagcgggg ggaggagcgg ggggaggagc ggggggagga 1620 gcggggggag gagcgggggg aggagcgggg ggaggagcgg ggggaggagc ggggggagga 1680 gcggggggag gagcgggggg aggagcgggg ggaggagcgg ggggaggagc ggggggagga 1740 gcggggggag gagcgggggg aggagcgggg ggaggagcgg ccagacgccg aaaacgggcc 1800 ccccccaaaa cacacccccc gggggtcgcg cgcggccctt taaagcggtg gcggcgggca 1860 gcccgggccc cccgcggccg agactagcga gttagacagg caagcactac tcgcctctgc 1920 acgcacatgc ttgcctgtca aactctacca ccccggcacg ctctctgtct ccatggcccg 1980 ccgccgccgc catcgcggcc cccgccgccc ccggccgccc gggcccacgg gcgccgtccc 2040 aaccgcacag tcccaggtaa cgagctcgaa ttaattcttg aagacgaaag ggcctcgtga 2100 tacgcctatt tttataggtt aatgtcatga taataatggt ttcttagggt cgacccaggt 2160 ggcacttttc ggggaaatgt gcgcggaacc cctatttgtt tatttttcta aatacattca 2220 aatatgtatc cgctcatgag acaataaccc tgataaatgc ttcaataata ttgaaaaagg 2280 aagagtatga gtattcaaca tttccgtgtc gcccttattc ccttttttgc ggcattttgc 2340 cttcctgttt ttgctcaccc agaaacgctg gtgaaagtaa aagatgctga agatcagttg 2400 ggtgcacgag tgggttacat cgaactggat ctcaacagcg gtaagatcct tgagagtttt 2460 cgccccgaag aacgttttcc aatgatgagc acttttaaag ttctgctatg tggcgcggta 2520 ttatcccgtg ttgacgccgg gcaagagcaa ctcggtcgcc gcatacacta ttctcagaat 2580 gacttggttg agtactcacc agtcacagaa aagcatctta cggatggcat gacagtaaga 2640 gaattatgca gtgctgccat aaccatgagt gataacactg cggccaactt acttctgaca 2700 acgatcggag gaccgaagga gctaaccgct tttttgcaca acatggggga tcatgtaact 2760 cgccttgatc gttgggaacc ggagctgaat gaagccatac caaacgacga gcgtgacacc 2820 acgatgcctg cagcaatggc aacaacgttg cgcaaactat taactggcga actacttact 2880 ctagcttccc ggcaacaatt aatagactgg atggaggcgg ataaagttgc aggaccactt 2940 ctgcgctcgg cccttccggc tggctggttt attgctgata aatctggagc cggtgagcgt 3000 gggtctcgcg gtatcattgc agcactgggg ccagatggta agccctcccg tatcgtagtt 3060 atctacacga cggggagtca ggcaactatg gatgaacgaa atagacagat cgctgagata 3120 ggtgcctcac tgattaagca ttggtaactg tcagaccaag tttactcata tatactttag 3180 attgatttaa aacttcattt ttaatttaaa aggatctagg tgaagatcct ttttgataat 3240 ctcatgacca aaatccctta acgtgagttt tcgttccact gagcgtcaga ccccgtagaa 3300 aagatcaaag gatcttcttg agatcctttt tttctgcgcg taatctgctg cttgcaaaca 3360 aaaaaaccac cgctaccagc ggtggtttgt ttgccggatc aagagctacc aactcttttt 3420 ccgaaggtaa ctggcttcag cagagcgcag ataccaaata ctgtccttct agtgtagccg 3480 tagttaggcc accacttcaa gaactctgta gcaccgccta catacctcgc tctgctaatc 3540 ctgttaccag tggctgctgc cagtggcgat aagtcgtgtc ttaccgggtt ggactcaaga 3600 cgatagttac cggataaggc gcagcggtcg ggctgaacgg ggggttcgtg cacacagccc 3660 agcttggagc gaacgaccta caccgaactg agatacctac agcgtgagct atgagaaagc 3720 gccacgcttc ccgaagggag aaaggcggac aggtatccgg taagcggcag ggtcggaaca 3780 ggagagcgca cgagggagct tccaggggga aacgcctggt atctttatag tcctgtcggg 3840 tttcgccacc tctgacttga gcgtcgattt ttgtgatgct cgtcaggggg gcggagccta 3900 tggaaaaacg ccagcaacgc ggccttttta cggttcctgg ccttttgctg gccttttgct 3960 cacatgttct ttcctgcgtt atcccctgat tctgtggata accgtattac cgcctttgag 4020 tgagctgata ccgctcgccg cagccgaacg accgagcgca gcgagtcagt gagcgaggaa 4080 gcggaagagc gcctgatgcg gtattttctc cttacgcatc tgtgcggtat ttcacaccgc 4140 ataggtcgac ctatggtgca ctctcagtac aatctgctct gatgccgcat agttaagcca 4200 gtatacactc cgctatcgct acgtgactgg gtcatggctg cgccccgaca cccgccaaca 4260 cccgctgacg cgccctgacg ggcttgtctg ctcccggcat ccgcttacag acaagctgtg 4320 accgtctccg ggagctgcat gtgtcagagg ttttcaccgt catcaccgaa acgcgcgagg 4380 cagccggcca ttatgcacga ccccgccccg acgccggcac gccgggggcc cgtggccgcg 4440 gcccgttggt cgaacccccg gccccgccca tccgcgccat ctgccatggg cggggcgcga 4500 gggcgggtgg gtccgcgccc cgccccgcat ggcatctcat taccgcccga tccggcggtt 4560 tccgcttccg ttccgcatgc taacgaggaa cgggcagggg gcggggcccg ggccccgact 4620 tcccggttcg gcggtaatga gatacgagcc ccgcgcgccc gttggccgtc cccgggcccc 4680 ccggtcccgc ccgccggacg ccgggaccaa cgggacggcg ggcggcccaa gggccgcccg 4740 ccttgccgcc cccccattgg ccggcgggcg ggaccgcccc aagggggcgg ggccgccggg 4800 taaaagaagt gagaacgcga agcgttcgca cttcgtccca atatatatat attattaggg 4860 cgaagtgcga gcactggcgc cgtgcccgac tccgcgccgg ccccgggggc gggcccgggc 4920 ggcggggggc gggtctctcc ggcgcacata aaggcccggc gcgaccgacg cccgcagacg 4980 gcgccggcca cgaacgacgg gagcggctgc ggagcacgcg gaccgggagc gggagtcgca 5040 gagggccgtc ggagcggacg gcgtcggcat cgcgacgccc cggctcggga tcgggatcgc 5100 atcggaaagg gacacgcgga cgcggggggg aaagacccgc ccaccccacc cacgaaacac 5160 aggggacgca ccccgggggc ctccgacgac agaaacccac cggtccgcct tttttgcacg 5220 ggtaagcacc ttgggtgggc ggaggagggg gggacgcggg ggtggaggag gggggacgcg 5280 ggggcggagg aggggggacg cgggggcgga ggagggggga cgcgggggcg gaggaggggg 5340 gacgcggggg cggaggaggg ggctcacccg cgttcgtgcc ttcccgcagg aggaacgtcc 5400 tcgtcgataa gctgatccat cgccaccatg gtgagcaagg gcgaggagct gttcaccggg 5460 gtggtgccca tcctggtcga gctggacggc gacgtaaacg gccacaagtt cagcgtgtcc 5520 ggcgagggcg agggcgatgc cacctacggc aagctgaccc tgaagttcat ctgcaccacc 5580 ggcaagctgc ccgtgccctg gcccaccctc gtgaccaccc tgacctacgg cgtgcagtgc 5640 ttcagccgct accccgacca catgaagcag cacgacttct tcaagtccgc catgcccgaa 5700 ggctacgtcc aggagcgcac catcttcttc aaggacgacg gcaactacaa gacccgcgcc 5760 gaggtgaagt tcgagggcga caccctggtg aaccgcatcg agctgaaggg catcgacttc 5820 aaggaggacg gcaacatcct ggggcacaag ctggagtaca actacaacag ccacaacgtc 5880 tatatcatgg ccgacaagca gaagaacggc atcaaggtga acttcaagat ccgccacaac 5940 atcgaggacg gcagcgtgca gctcgccgac cactaccagc agaacacccc catcggcgac 6000 ggccccgtgc tgctgcccga caaccactac ctgagcaccc agtccgccct gagcaaagac 6060 cccaacgaga agcgcgatca catggtcctg ctggagttcg tgaccgccgc cgggatcact 6120 ctcggcatgg acgagctgta caagtaaagc ggccaacttg tttattgcag cttataatgg 6180 ttacaaataa agcaatagca tcacaaattt cacaaataaa gcattttttt cactgcattc 6240 tagttgtggt ttgtccaaac tcatcaatgt atcttatcat gtctggatcg gtttgaagat 6300 cttccgatgt acgggccaga tatacgcgtt gacattgatt attgactagt tattaatagt 6360 aatcaattac ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta 6420 cggtaaatgg cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga 6480 cgtatgttcc catagtaacg ccaataggga ctttccattg acgtcaatgg gtggactatt 6540 tacggtaaac tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgcccccta 6600 ttgacgtcaa tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg 6660 actttcctac ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt 6720 ttt 6723 <210> 2 <211> 954 <212> DNA <213> Homo sapiens <400> 2 atgtacaaca tgatggagac ggagctgaag ccgccgggcc cgcagcaaac ttcggggggc 60 ggcggcggca actccaccgc ggcggcggcc ggcggcaacc agaaaaacag cccggaccgc 120 gtcaagcggc ccatgaatgc cttcatggtg tggtcccgcg ggcagcggcg caagatggcc 180 caggagaacc ccaagatgca caactcggag atcagcaagc gcctgggcgc cgagtggaaa 240 cttttgtcgg agacggagaa gcggccgttc atcgacgagg ctaagcggct gcgagcgctg 300 cacatgaagg agcacccgga ttataaatac cggccccggc ggaaaaccaa gacgctcatg 360 aagaaggata agtacacgct gcccggcggg ctgctggccc ccggcggcaa tagcatggcg 420 agcggggtcg gggtgggcgc cggcctgggc gcgggcgtga accagcgcat ggacagttac 480 gcgcacatga acggctggag caacggcagc tacagcatga tgcaggacca gctgggctac 540 ccgcagcacc cgggcctcaa tgcgcacggc gcagcgcaga tgcagcccat gcaccgctac 600 gacgtgagcg ccctgcagta caactccatg accagctcgc agacctacat gaacggctcg 660 cccacctaca gcatgtccta ctcgcagcag ggcacccctg gcatggctct tggctccatg 720 ggttcggtgg tcaagtccga ggccagctcc agcccccctg tggttacctc ttcctcccac 780 tccagggcgc cctgccaggc cggggacctc cgggacatga tcagcatgta tctccccggc 840 gccgaggtgc cggaacccgc cgcccccagc agacttcaca tgtcccagca ctaccagagc 900 ggcccggtgc ccggcacggc cattaacggc acactgcccc tctcacacat gtga 954 <210> 3 <211> 1083 <212> DNA <213> Homo sapiens <400> 3 atggcgggac acctggcttc ggatttcgcc ttctcgcccc ctccaggtgg tggaggtgat 60 gggccagggg ggccggagcc gggctgggtt gatcctcgga cctggctaag cttccaaggc 120 cctcctggag ggccaggaat cgggccgggg gttgggccag gctctgaggt gtgggggatt 180 cccccatgcc ccccgccgta tgagttctgt ggggggatgg cgtactgtgg gccccaggtt 240 ggagtggggc tagtgcccca aggcggcttg gagacctctc agcctgaggg cgaagcagga 300 gtcggggtgg agagcaactc cgatggggcc tccccggagc cctgcaccgt cacccctggt 360 gccgtgaagc tggagaagga gaagctggag caaaacccgg aggagtccca ggacatcaaa 420 gctctgcaga aagaactcga gcaatttgcc aagctcctga agcagaagag gatcaccctg 480 ggatatacac aggccgatgt ggggctcacc ctgggggttc tatttgggaa ggtattcagc 540 caaacgacca tctgccgctt tgaggctctg cagcttagct tcaagaacat gtgtaagctg 600 cggcccttgc tgcagaagtg ggtggaggaa gctgacaaca atgaaaatct tcaggagata 660 tgcaaagcag aaaccctcgt gcaggcccga aagagaaagc gaaccagtat cgagaaccga 720 gtgagaggca acctggagaa tttgttcctg cagtgcccga aacccacact gcagcagatc 780 agccacatcg cccagcagct tgggctcgag aaggatgtgg tccgagtgtg gttctgtaac 840 cggcgccaga agggcaagcg atcaagcagc gactatgcac aacgagagga ttttgaggct 900 gctgggtctc ctttctcagg gggaccagtg tcctttcctc tggccccagg gccccatttt 960 ggtaccccag gctatgggag ccctcacttc actgcactgt actcctcggt ccctttccct 1020 gagggggaag cctttccccc tgtctccgtc accactctgg gctctcccat gcattcaaac 1080 tga 1083 <210> 4 <211> 918 <212> DNA <213> Homo sapiens <400> 4 atgagtgtgg atccagcttg tccccaaagc ttgccttgct ttgaagcatc cgactgtaaa 60 gaatcttcac ctatgcctgt gatttgtggg cctgaagaaa actatccatc cttgcaaatg 120 tcttctgctg agatgcctca cacggagact gtctctcctc ttccttcctc catggatctg 180 cttattcagg acagccctga ttcttccacc agtcccaaag gcaaacaacc cacttctgca 240 gagaagagtg tcgcaaaaaa ggaagacaag gtcccggtca agaaacagaa gaccagaact 300 gtgttctctt ccacccagct gtgtgtactc aatgatagat ttcagagaca gaaatacctc 360 agcctccagc agatgcaaga actctccaac atcctgaacc tcagctacaa acaggtgaag 420 acctggttcc agaaccagag aatgaaatct aagaggtggc agaaaaacaa ctggccgaag 480 aatagcaatg gtgtgacgca gaaggcctca gcacctacct accccagcct ttactcttcc 540 taccaccagg gatgcctggt gaacccgact gggaaccttc caatgtggag caaccagacc 600 tggaacaatt caacctggag caaccagacc cagaacatcc agtcctggag caaccactcc 660 tggaacactc agacctggtg cacccaatcc tggaacaatc aggcctggaa cagtcccttc 720 tataactgtg gagaggaatc tctgcagtcc tgcatgcagt tccagccaaa ttctcctgcc 780 agtgacttgg aggctgcctt ggaagctgct ggggaaggcc ttaatgtaat acagcagacc 840 actaggtatt ttagtactcc acaaaccatg gatttattcc taaactactc catgaacatg 900 caacctgaag acgtgtga 918 <210> 5 <211> 1440 <212> DNA <213> Homo sapiens <400> 5 atgaggcagc cacctggcga gtctgacatg gctgtcagcg acgcgctgct cccatctttc 60 tccacgttcg cgtctggccc ggcgggaagg gagaagacac tgcgtcaagc aggtgccccg 120 aataaccgct ggcgggagga gctctcccac atgaagcgac ttcccccagt gcttcccggc 180 cgcccctatg acctggcggc ggcgaccgtg gccacagacc tggagagcgg cggagccggt 240 gcggcttgcg gcggtagcaa cctggcgccc ctacctcgga gagagaccga ggagttcaac 300 gatctcctgg acctggactt tattctctcc aattcgctga cccatcctcc ggagtcagtg 360 gccgccaccg tgtcctcgtc agcgtcagcc tcctcttcgt cgtcgccgtc gagcagcggc 420 cctgccagcg cgccctccac ctgcagcttc acctatccga tccgggccgg gaacgacccg 480 ggcgtggcgc cgggcggcac gggcggaggc ctcctctatg gcagggagtc cgctccccct 540 ccgacggctc ccttcaacct ggcggacatc aacgacgtga gcccctcggg cggcttcgtg 600 gccgagctcc tgcggccaga attggacccg gtgtacattc cgccgcagca gccgcagccg 660 ccaggtggcg ggctgatggg caagttcgtg ctgaaggcgt cgctgagcgc ccctggcagc 720 gagtacggca gcccgtcggt catcagcgtc agcaaaggca gccctgacgg cagccacccg 780 gtggtggtgg cgccctacaa cggcgggccg ccgcgcacgt gccccaagat caagcaggag 840 gcggtctctt cgtgcaccca cttgggcgct ggaccccctc tcagcaatgg ccaccggccg 900 gctgcacacg acttccccct ggggcggcag ctccccagca ggactacccc gaccctgggt 960 cttgaggaag tgctgagcag cagggactgt caccctgccc tgccgcttcc tcccggcttc 1020 catccccacc cggggcccaa ttacccatcc ttcctgcccg atcagatgca gccgcaagtc 1080 ccgccgctcc attaccaaga gctcatgcca cccggttcct gcatgccaga ggagcccaag 1140 ccaaagaggg gaagacgatc gtggccccgg aaaaggaccg ccacccacac ttgtgattac 1200 gcgggctgcg gcaaaaccta cacaaagagt tcccatctca aggcacacct gcgaacccac 1260 acaggtgaga aaccttacca ctgtgactgg gacggctgtg gatggaaatt cgcccgctca 1320 gatgaactga ccaggcacta ccgtaaacac acggggcacc gcccgttcca gtgccaaaaa 1380 tgcgaccgag cattttccag gtcggaccac ctcgccttac acatgaagag gcatttttaa 1440                                                                         1440 <210> 6 <211> 630 <212> DNA <213> Homo sapiens <400> 6 atgggctccg tgtccaacca gcagtttgca ggtggctgcg ccaaggcggc agaagaggcg 60 cccgaggagg cgccggagga cgcggcccgg gcggcggacg agcctcagct gctgcacggt 120 gcgggcatct gtaagtggtt caacgtgcgc atggggttcg gcttcctgtc catgaccgcc 180 cgcgccgggg tcgcgctcga ccccccagtg gatgtctttg tgcaccagag taagctgcac 240 atggaagggt tccggagctt gaaggagggt gaggcagtgg agttcacctt taagaagtca 300 gccaagggtc tggaatccat ccgtgtcacc ggacctggtg gagtattctg tattgggagt 360 gagaggcggc caaaaggaaa gagcatgcag aagcgcagat caaaaggaga caggtgctac 420 aactgtggag gtctagatca tcatgccaag gaatgcaagc tgccacccca gcccaagaag 480 tgccacttct gccagagcat cagccatatg gtagcctcat gtccgctgaa ggcccagcag 540 ggccctagtg cacagggaaa gccaacctac tttcgagagg aagaagaaga aatccacagc 600 cctaccctgc tcccggaggc acagaattga 630 <210> 7 <211> 1365 <212> DNA <213> Homo sapiens <400> 7 ctggattttt ttcgggtagt ggaaaaccag cagcctcccg cgacgatgcc cctcaacgtt 60 agcttcacca acaggaacta tgacctcgac tacgactcgg tgcagccgta tttctactgc 120 gacgaggagg agaacttcta ccagcagcag cagcagagcg agctgcagcc cccggcgccc 180 agcgaggata tctggaagaa attcgagctg ctgcccaccc cgcccctgtc ccctagccgc 240 cgctccgggc tctgctcgcc ctcctacgtt gcggtcacac ccttctccct tcggggagac 300 aacgacggcg gtggcgggag cttctccacg gccgaccagc tggagatggt gaccgagctg 360 ctgggaggag acatggtgaa ccagagtttc atctgcgacc cggacgacga gaccttcatc 420 aaaaacatca tcatccagga ctgtatgtgg agcggcttct cggccgccgc caagctcgtc 480 tcagagaagc tggcctccta ccaggctgcg cgcaaagaca gcggcagccc gaaccccgcc 540 cgcggccaca gcgtctgctc cacctccagc ttgtacctgc aggatctgag cgccgccgcc 600 tcagagtgca tcgacccctc ggtggtcttc ccctaccctc tcaacgacag cagctcgccc 660 aagtcctgcg cctcgcaaga ctccagcgcc ttctctccgt cctcggattc tctgctctcc 720 tcgacggagt cctccccgca gggcagcccc gagcccctgg tgctccatga ggagacaccg 780 cccaccacca gcagcgactc tgaggaggaa caagaagatg aggaagaaat cgatgttgtt 840 tctgtggaaa agaggcaggc tcctggcaaa aggtcagagt ctggatcacc ttctgctgga 900 ggccacagca aacctcctca cagcccactg gtcctcaaga ggtgccacgt ctccacacat 960 cagcacaact acgcagcgcc tccctccact cggaaggact atcctgctgc caagagggtc 1020 aagttggaca gtgtcagagt cctgagacag atcagcaaca accgaaaatg caccagcccc 1080 aggtcctcgg acaccgagga gaatgtcaag aggcgaacac acaacgtctt ggagcgccag 1140 aggaggaacg agctaaaacg gagctttttt gccctgcgtg accagatccc ggagttggaa 1200 aacaatgaaa aggcccccaa ggtagttatc cttaaaaaag ccacagcata catcctgtcc 1260 gtccaagcag aggagcaaaa gctcatttct gaagaggact tgttgcggaa acgacgagaa 1320 cagttgaaac acaaacttga acagctacgg aactcttgtg cgtaa 1365 <210> 8 <211> 749 <212> DNA <213> Artificial Sequence <220> <223> Artificial sequence <400> 8 atggtgagca agggcgagga gctgttcacc ggggtggtgc ccatcctggt cgagctggac 60 ggcgacgtaa acggccacaa gttcagcgtg tccggcgagg gcgagggcga tgccacctac 120 ggcaagctga ccctgaagtt catctgcacc accggcaagc tgcccgtgcc ctggcccacc 180 ctcgtgacca ccctgaccta cggcgtgcag tgcttcagcc gctaccccga ccacatgaag 240 cagcacgact tcttcaagtc cgccatgccc gaaggctacg tccaggagcg caccatcttc 300 ttcaaggacg acggcaacta caagacccgc gccgaggtga agttcgaggg cgacaccctg 360 gtgaaccgca tcgagctgaa gggcatcgac ttcaaggagg acggcaacat cctggggcac 420 aagctggagt acaactacaa cagccacaac gtctatatca tggccgacaa gcagaagaac 480 ggcatcaagg tgaacttcaa gatccgccac aacatcgagg acggcagcgt gcagctcgcc 540 gaccactacc agcagaacac ccccatcggc gacggccccg tgctgctgcc cgacaaccac 600 tacctgagca cccagtccgc cctgagcaaa gaccccaacg agaagcgcga tcacatggtc 660 ctgctggagt tcgtgaccgc cgccgggatc actctcggca tggacgagct gtactaatga 720 ccccgtaatt gattactatt aataactaa 749 <210> 9 <211> 678 <212> DNA <213> Artificial Sequence <220> <223> Artificial sequence <400> 9 atggcctcct ccgagaacgt catcaccgag ttcatgcgct tcaaggtgcg catggagggc 60 accgtgaacg gccacgagtt cgagatcgag ggcgagggcg agggccgccc ctacgagggc 120 cacaacaccg tgaagctgaa ggtgaccaag ggcggccccc tgcccttcgc ctgggacatc 180 ctgtcccccc agttccagta cggctccaag gtgtacgtga agcaccccgc cgacatcccc 240 gactacaaga agctgtcctt ccccgagggc ttcaagtggg agcgcgtgat gaacttcgag 300 gacggcggcg tggcgaccgt gacccaggac tcctccctgc aggacggctg cttcatctac 360 aaggtgaagt tcatcggcgt gaacttcccc tccgacggcc ccgtgatgca gaagaagacc 420 atgggctggg aggcctccac cgagcgcctg tacccccgcg acggcgtgct gaagggcgag 480 acccacaagg ccctgaagct gaaggacggc ggccactacc tggtggagtt caagtccatc 540 tacatggcca agaagcccgt gcagctgccc ggctactact acgtggacgc caagctggac 600 atcacctccc acaacgagga ctacaccatc gtggagcagt acgagcgcac cgagggccgc 660 caccacctgt tcctgtag 678  

Claims (4)

2 종 이상의 표적 유전자를 각각 별도의 헤르페스 심플렉스 바이러스 앰플리콘 플라스미드(Herpes simplex virus amplicon plasmid)에 재조합시켜 얻어진 2 종 이상의 재조합 플라스미드를, fHSV△pac△27 0+ 및 pEBHICP27과 함께 수용 세포에 공동-형질도입시켜 패키징(packaging)시키는 단계를 포함하는, 2 종 이상의 표적 유전자를 동시에 함유하는 바이러스의 제조방법.Two or more recombinant plasmids obtained by recombining two or more target genes into a separate herpes simplex virus amplicon plasmid, respectively, were co--received together with fHSVΔpacΔ27 0+ and pEBHICP27 to recipient cells. A method for producing a virus containing two or more target genes simultaneously, comprising the steps of transducing and packaging. 제1항에 있어서, 상기 헤르페스 심플렉스 바이러스 앰플리콘 플라스미드가 서열번호 1의 염기서열을 갖는 것을 특징으로 하는 제조방법.The method according to claim 1, wherein the herpes simplex virus amplicon plasmid has a nucleotide sequence of SEQ ID NO: 1. 제1항에 있어서, 상기 표적 유전자가 서열번호 2 내지 7의 유전자로부터 2 종 이상 선택된 역분화 유도 인자를 코딩하는 유전자인 것을 특징으로 하는 제조방법.The method according to claim 1, wherein the target gene is a gene encoding at least two differentiation induction factors selected from the genes of SEQ ID NOs: 2 to 7. 삭제delete
KR1020080072102A 2008-07-24 2008-07-24 Method for producing a virus containing two or more target genes simultaneously KR101055305B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020080072102A KR101055305B1 (en) 2008-07-24 2008-07-24 Method for producing a virus containing two or more target genes simultaneously

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020080072102A KR101055305B1 (en) 2008-07-24 2008-07-24 Method for producing a virus containing two or more target genes simultaneously

Publications (2)

Publication Number Publication Date
KR20100011054A KR20100011054A (en) 2010-02-03
KR101055305B1 true KR101055305B1 (en) 2011-08-09

Family

ID=42085569

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020080072102A KR101055305B1 (en) 2008-07-24 2008-07-24 Method for producing a virus containing two or more target genes simultaneously

Country Status (1)

Country Link
KR (1) KR101055305B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190127266A (en) 2018-05-04 2019-11-13 (주)지뉴인텍 A recombinant vector for gene delivery, and a composition for preventing or treating neurodegenerative diseases using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100011053A (en) * 2008-07-24 2010-02-03 차의과학대학교 산학협력단 Method for preparing induced pluripotent stem cells using herpes simplex amplicon viruses containing reprogramming-inducing genes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100011053A (en) * 2008-07-24 2010-02-03 차의과학대학교 산학협력단 Method for preparing induced pluripotent stem cells using herpes simplex amplicon viruses containing reprogramming-inducing genes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cytometry, 2001, 44(2):93~99
Mol. Med., 1997, 3(12):813-825
Molecular Therapy, 2001, 3(4):591-601*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190127266A (en) 2018-05-04 2019-11-13 (주)지뉴인텍 A recombinant vector for gene delivery, and a composition for preventing or treating neurodegenerative diseases using the same

Also Published As

Publication number Publication date
KR20100011054A (en) 2010-02-03

Similar Documents

Publication Publication Date Title
CA2549477A1 (en) Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin
CN111363046A (en) Chimeric antigen receptor targeting NKG2D, chimeric antigen receptor T cell, and preparation method and application thereof
CN109797167B (en) Plasmid, system, preparation and preparation method for targeted knockout of human papilloma virus URR gene
CN114438130B (en) Beta-globin recombinant lentiviral vector and application thereof
CN111603477B (en) Application of annular RNA in preparation of therapeutic drugs for systemic lupus erythematosus
CN112601811A (en) Production of engineered cells and uses thereof
KR101055305B1 (en) Method for producing a virus containing two or more target genes simultaneously
KR101061541B1 (en) Method for preparing reverse differentiated pluripotent stem cells using herpes simplex amplicon virus containing reverse differentiation inducing factor
CN110305219B (en) Use of T cell comprising Chimeric Antigen Receptor (CAR) modification for preparing cell medicament
CN111154003B (en) Cas9 fusion protein for improving gene knock-in efficiency and exogenous gene knock-in integration system
CA2814713A1 (en) Cardiac induced pluripotent stem cells and methods of use in repair and regeneration of myocardium
CN113980965B (en) Bifunctional expression vector and chimeric antigen receptor modified macrophage
CA2348745A1 (en) Dna molecules encoding muc-1 and use thereof in tumor vaccination
KR100988289B1 (en) Gene constructs comprising two or more reprogramming-inducing genes and method for preparing induced pluripotent stem cells using the same
CN110643694B (en) Application of circular RNA circPOLR2A in systemic lupus erythematosus detection marker and preparation of therapeutic drug
CN115786270A (en) Engineered macrophages and their use in the treatment of fibrotic diseases
CN114457119A (en) Application of lentiviral vector in preparation of drug for treating beta-thalassemia
CN110885790B (en) Targeting MMSA-1 chimeric antigen receptor modified T lymphocyte and preparation method and application thereof
KR20230029918A (en) Multidonor CD4+ T cells expressing IL-10 and uses thereof
CN115340998B (en) Recombinant viral vector, recombinant virus containing recombinant viral vector, novel coronavirus vaccine and application of novel coronavirus vaccine
CN115011601B (en) shRNA (short hairpin ribonucleic acid) interfering with JUND expression, recombinant adeno-associated virus vector and application thereof
KR101687318B1 (en) Ecdysone receptor-based transgene inducible vector
KR100981995B1 (en) FRM-EGF fusion protein and composition for wound healing comprising the same
CN110724710A (en) Vector for controlling pig PFKM expression and application thereof
CN110564693A (en) An isolated cell or cell line

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20140725

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20160729

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20170728

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20180726

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20190729

Year of fee payment: 9